EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

WHEN SHOULD RWE STUDIES BE PRIORITIZED FOR REIMBURSEMENT? INSIGHTS FROM THE CANADIAN PERSPECTIVE

Jennifer Boss iD, Laura Shulak, Trisha Rao, Candice Tam, Shannon M Sullivan

International Journal of Technology Assessment in Health Care · 2026

DOI: 10.1017/s0266462325103401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Technology Assessment in Health Care, 2026. Verfasst von Jennifer Boss und 4 weiteren Autor:innen. Beteiligte Einrichtung: https://ror.org/00gttkw41PPD Evidera Health Economics & Market Access, Thermo Fisher Scientific, UK. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Reimbursement Mechanisms, Insurance, Health, Reimbursement. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the increasing importance of real-world evidence (RWE) in health technology assessment (HTA) decision-making, we aimed to assess RWE use in Canadian HTA and collect stakeholder insights on when RWE generation should be prioritized in HTA.We found that RWE was included in one-third of Canadian Drug Agency-L'Agence des médicaments du Canada (CDA-AMC) reimbursement reviews (2017-2022). To further understand drivers of RWE generation for reimbursement, consultations were held with stakeholders (pharmaceutical industry representatives, payers, and patient advocates) to obtain insights in Canada and other global markets. Stakeholders highlighted the value of RWE to complement randomized controlled trials (RCT) data, as well as the need to consider feasibility and multiple stakeholder perspectives.Our findings indicate there is a need to further support the practical implementation of RWE in policy decision-making. A framework providing guidance on when to prioritize RWE studies for reimbursement would provide value and could be tailored by region.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalReimbursement MechanismsInsurance, Health, ReimbursementCanadaHumansDecision MakingPolicy MakingHealth Policy

Stichwörter der Autor:innen

HTAhealth policypharmaceuticalsreal-world evidencereimbursement

Autor:innen und Institutionen

  • https://ror.org/00gttkw41PPD Evidera Health Economics & Market Access, Thermo Fisher Scientific, UK.
  • https://ror.org/00gttkw41PPD Evidera Health Economics & Market Access, Thermo Fisher Scientific, Canada.
  • https://ror.org/00gttkw41PPD Evidera Health Economics & Market Access, Thermo Fisher Scientific, France.

ORCID-Profile: Jennifer Boss

Zitieren

APA

Boss, J., Shulak, L., Rao, T., Tam, C., & Sullivan, S. M. (2026). WHEN SHOULD RWE STUDIES BE PRIORITIZED FOR REIMBURSEMENT? INSIGHTS FROM THE CANADIAN PERSPECTIVE. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462325103401

Vancouver

Boss J, Shulak L, Rao T, Tam C, Sullivan SM. WHEN SHOULD RWE STUDIES BE PRIORITIZED FOR REIMBURSEMENT? INSIGHTS FROM THE CANADIAN PERSPECTIVE. International Journal of Technology Assessment in Health Care. 2026. doi:10.1017/s0266462325103401

BibTeX
@article{Boss2026,
  author = {Boss, Jennifer and Shulak, Laura and Rao, Trisha and Tam, Candice and Sullivan, Shannon M},
  title = {WHEN SHOULD RWE STUDIES BE PRIORITIZED FOR REIMBURSEMENT? INSIGHTS FROM THE CANADIAN PERSPECTIVE},
  journal = {International Journal of Technology Assessment in Health Care},
  year = {2026},
  doi = {10.1017/s0266462325103401}
}
Kostenlos starten →